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Abstract
Bacterial infections are the leading cause of death in people with a spinal cord injury (SCI). Bacteriophages (phages) are
viruses that solely infect and kill bacteria. The idea of using phages to treat bacterial infections, i.e., phage therapy, is very
promising and potentially allows a more specific and personalized treatment of bacterial infections than antibiotics. While
multi-drug resistant infections affect individuals from the general population, alternative therapeutic options are especially
warranted in high-risk populations, such as individuals with SCI. However, more clinical data must be collected before
phage therapy can be implemented in clinical practice, with numerous possible, subsequent applications.
Main text
Suffering a spinal cord injury (SCI) is a life-disrupting
event with devastating consequences for the individuals
and their communities. Advances in primary care, rehabi-
litation interventions, life-long medical management and
institutionalized social support have saved many lives and
allow individuals with a SCI to adapt to their new condition
and fully participate in social and economic life, at least in
high-income countries [1]. However, even apart from the
first rehabilitation, people with SCI have more and rela-
tively longer hospital admissions on average than people
without SCI, resulting in a higher risk for hospital-acquired
illness [2]. Multi-drug resistant (MDR) microbes, poten-
tially hospital-acquired, are a frequent culprit [3]. Despite
all advances in modern medicine, the life expectancy in the
SCI population is relatively shorter than in the general
population, and the leading cause of death in persons sur-
viving the first year post-injury after SCI are infectious
diseases, mostly respiratory, urinary tract or skin and bone
related [4].
In the context of increasing MDR, current treatment
options are failing to provide sufficient therapeutic benefit
to individuals with SCI with bacterial infections. Not only
does infection severely impact life expectancy and quality
of life, but it also increases health care burden and costs.
Therefore, the implementation of new treatment strategies
and the development of products with reliable performance
in daily clinical practice is indispensable.
Phages and therapeutic application
Bacteriophages [5, 6] (phages), from the Greek word
βακτήριoν (baktérion) and ϕαγεῖν (phageín) (meaning:
“bacteria eaters”), have the potential to complement and
optimize current treatment strategies in infectious diseases
and other medical fields (Fig. 1). Phages are naturally-
existing viruses that specifically kill bacteria, including
MDR strains, while eukaryotic cells are not infected. Unlike
antibiotics, phages are highly specific to the bacterial spe-
cies, or even to the bacterial strain.
The idea of using phages to treat bacterial infections,
i.e., phage therapy, is not new. In 1919, Félix d’ Hérelle
conducted the first initial experiments with phages to cure
bacterial infections in humans and successfully treated
several children at the Hospital des Enfants Malades in
Paris [6]. However, the discovery of penicillin a decade
later (1928) deterred the interest for phages in the Western
world. At present, phage therapy is a well-accepted and
registered therapy in post-Soviet countries like Georgia,
Ukraine, and Russia. However, amidst the growing con-
cerns of antimicrobial resistance, the use of phages as a
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target therapy against bacterial pathogens has gained a
renewed interest worldwide. While reports of successfully
applied phage therapies for different medical indications
have been published and case reports demonstrate suc-
cessful treatment outcomes for some patients, there is still a
lack of high-quality evidence to support the use of this
treatment strategy. Nevertheless, more and more academic
and industrial consortia are entering the field, aiming to
implement phage and phage-related therapeutic pathways
in routine clinical practice.
Phage therapy in the context of SCI
Several treatment strategies and recent advances in phage
therapy could be of specific interest for the SCI population,
such as urinary tract infections (UTIs), as well as respiratory
and skin or bone infections. While none of the currently
available literature or case reports for phage therapy involve
the treatment of individuals with SCI, their experiences are
relevant and illustrate future potential applications for the
SCI population.
Virtually every individual with SCI suffers from neuro-
genic lower urinary tract dysfunction, a condition leading to
recurrent UTIs in many patients. UTI is associated with a
considerable morbidity and mortality and substantially
affects the quality of life. In vitro results of a study per-
formed by our group found high lytic activity of a Georgian,
commercially-available and licensed phage product against
most common bacterial strains detected in UTIs from
individuals with SCI [7]. A subsequent, randomized con-
trolled trial (RCT) [8] comparing intravesical instillations of
either a phage or a placebo versus standard-of-care (SOC)
antibiotic treatment showed that intravesical phage therapy
was non-inferior to the SOC, but not superior to placebo
bladder irrigation in terms of efficacy in treating UTIs in
patients undergoing transurethral resection of the prostate.
Moreover, the phage safety profile seemed to be favorable
compared to the other treatment options. However, the
study did not include individuals with SCI or patients per-
forming intermittent self-catheterization, which would be
more relevant populations for understanding the value of
phage therapy for SCI. In a step to address this, a RCT in
this populations, using phages specifically engineered to
treat catheter-associated UTIs, will be starting soon (http://
p3.snf.ch/project-189957). Results from other upcoming
clinical trials (clinicaltrials.gov: NCT04287478,
NCT04191148) focusing on UTI will further enhance our
understanding.
Another main focus for phage therapy is the treatment
of respiratory tract infections particularly for patients with
cystic fibrosis (CF), who are at an increased risk of
developing MDR bacterial infections. After several emer-
gency treatments with phages for CF patients, two clinical
trials are starting for the treatment of Pseudomonas aeru-
ginosa infections (clinicaltrials.gov: NCT04684641,
NCT04596319). This is worth mentioning, as even if CF
or P. aeruginosa lung infections are not directly SCI
related, insights in terms of potential strategies for phage
delivery (e.g., topical/inhalation, oral, intravenous), to
optimize therapeutic effects by degradation of biofilms and
enhancing bacteria phage interactions should not be
underestimated for all kind of bacterial infections. Addi-
tionally, the Food and Drug Administration (FDA) recently
authorized the use of phage for the treatment of bacterial
pneumonia co-infections in COVID-19 patients (clin-
icaltrials.gov: NCT04636554).
Individuals with SCI are frequently afflicted by pressure
sores often aggravated by superinfections and potentially
causing osteomyelitis. Phages provide an interesting plat-
form in treating osteomyelitis and peri-prosthetic joint
infection (PJI) [9], resulting often in positive clinical out-
comes. Most case reports have entailed surgical procedures
to apply phage directly to the site of infection, as well as
debridement of the infection site or prosthesis exchange, but
intravenous application has been more recently reported.
Published reports for skin indications are less frequent: for
one patient who underwent amputation of the lower limbs,
septic episodes caused by a polymicrobial infected pressure
sore were controlled with phage therapy [10]. The ability of
phages to both degrade biofilms and eliminate bacteria
Fig. 1 Transmission electron microscopy (TEM) image of bacter-
iophages (phages) produced to treat a patient with a multi-
resistant Enterobacter cloacae urinary tract infection. The phages
are composed of a capsid (containing the genome) connected to a
contractile tail with protruding tail fibers which mediate interaction
with bacterial surface receptors. Phages are highly host specific,
meaning a given phage is capable of infecting only a narrow host range
of bacteria (typically down to the species level). TEM image was
kindly provided by Matthew Dunne, Ph.D., and Jiemin Du, M.Sc.,
from the Institute of Food, Nutrition and Health, ETH Zürich, Zürich,
Switzerland.
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represents a great potential for the treatment of skin and
bone infections in individuals with SCI. While preclinical
studies and case reports have shown promising results,
clinical trials are still needed to evaluate phage therapy
more vigorously. The FDA has recently granted orphan
drug designation of phage therapy for the treatment of
osteomyelitis and PJI, which indicates that trials are soon to
follow [9].
Phage therapy: next steps and other areas of
application
Why has the Western world not yet implemented phage
therapy, despite the long history, the high potential, and the
urgent need? There are several reasons. Most of the time,
antibiotic therapy has provided, and still does provide,
excellent results for patients. Hence, the interest to imple-
ment new therapeutic strategies to treat bacterial infections
have long-since been of low priority, especially for strate-
gies with complex regulatory pathways and low potential
for financial returns, such as phage therapy. At present,
phage therapy is not authorized outside of clinical studies in
most countries, but it is occasionally used as an experi-
mental treatment in emergency cases (i.e. compassionate
use). Considering that phages are host-specific and target
only a subset of bacterial strains, a broad arsenal of different
phages is required to find the right phage for each patient.
This has posed considerable problems regarding regulations
and manufacturing compared to small-molecule develop-
ment. In this perspective, recent approval by the FDA for a
phage collection for personalized therapies (PhageBankTM
by the Biological Defense Research Directorate of the U.S.
Naval Medical Research Center (NMRC), which will be
used in the clinical trial NCT04287478), as well as the
Belgian regulatory approach (Belgium Phage Active Phar-
maceutical Ingredient monograph (version 1.0) for magis-
tral phage preparation: http://www.mdpi.com/1999-4915/
10/2/64/s1) of allowing custom-made phage medicines for
individual patients, provide light at the end of the tunnel and
open the gates for phage therapy to progress into clinical
medicine.
Advances in molecular biology and bioengineering also
extend the field for even more phage-related medical
applications. On one hand, phages can be engineered to
enhance their host range or to augment their antimicrobial
activity. Another exciting strategy is to include payload
genes in a phage genome so that host bacteria would pro-
duce and dispense specific proteins (e.g., with immune-
modulatory or anti-inflammatory effects) at the site of
infection. The ability of phage to cross the blood-brain-
barrier [11] could further allow their use as a drug delivery
vectors to the central nervous system, an idea of specific
interest in patients with acute SCI.
Conclusions
Phage therapy is very promising and potentially allows a
more specific and personalized treatment of bacterial
infections. While MDR infections affect individuals from
the general population, alternative therapeutic options are
especially warranted in high-risk populations, such as
individuals with SCI. However, which phages to use and
how exactly to apply them (concentration, administration
route, duration, posology) is challenging to define. Only
once more clinical data has been obtained will it be possible
to implement phage therapy in clinical practice, and thus
open the door for numerous future applications.
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